GlassScriptPhysician profile
Victoria Kean
NPI 1942253844
$1,951.76
in general payments reported to CMS, 2019-2025
27 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $171 · 2021: $292 · 2022: $549 · 2023: $349 · 2024: $157 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.07 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $406.19 | 2019-2023 | |
| Astellas Pharma US INC | $363.55 | 2019-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $354.95 | 2020-2022 | |
| Hologic Sales and Service, LLC | $100.06 | 2019-2023 | Thinprep 2000 Processor, Aptima |
| Mayne Pharma Commercial LLC | $85.16 | 2023-2025 | |
| Daiichi Sankyo INC. | $77.91 | 2022-2024 | Injectafer |
| Amag Pharmaceuticals, INC. | $66.40 | 2019-2022 | |
| Exeltis, USA INC. | $55.82 | 2019-2025 | Slynd |
| Pfizer INC. | $51.43 | 2021-2024 | |
| Exact Sciences Corporation | $42.02 | 2023-2025 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $40.79 | 2019-2020 | |
| Gynesonics, INC. | $40.17 | 2023-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Avion Pharmaceuticals | $29.42 | 2019 | |
| Sage Therapeutics, LLC | $26.82 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $24.02 | 2023 | Myfembree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $22.51 | 2019 | |
| Coopersurgical, INC. | $21.25 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $20.74 | 2023 | Vivjoa |
| Agile Therapeutics, INC. | $17.85 | 2022 | |
| Amgen INC. | $17.33 | 2019 | |
| Medicem INC. | $16.52 | 2020 | |
| Organon LLC | $15.45 | 2024 | |
| Allergan, INC. | $15.41 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.47 | 2020 | |
| Evofem Biosciences, INC. | $13.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.76 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Kean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.